Trial ID or NCT#

NCT02736578

Status

not recruiting iconNOT RECRUITING

Purpose

This phase 1-2 trial studies the side effects and best dose of cetuximab-IRDye 800CW when used with intraoperative imaging, to determine the utility of cetuximab-IRDye 800CW to identify and assess pancreatic cancer in patients undergoing surgery to remove the tumor. Cetuximab-IRDye 800CW may help doctors better identify cancer in the operating room by making the cancer visible when viewed through a fluorescent imaging system.

Official Title

Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

George A. Poultsides, MD, MS, FACS
George A. Poultsides, MD, MS, FACS
Hepatobiliary surgeon, Pancreatic surgeon, Liver surgeon, Sarcoma specialist, Gastrointestinal specialist, Minimally invasive surgeon
Professor of Surgery (General Surgery) at the Stanford University Medical Center
Eben Rosenthal
Eben Rosenthal
Otolaryngologist, Head and neck surgeon
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiology (Molecular Imaging Program at Stanford)

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061